Funding

Neurodegenerative diseases and dementia

Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration or death of nerve cells. They include Alzheimer's disease and other dementias, Parkinson's disease, Huntington's disease, motor neurone disease, Creutzfeldt-Jakob disease and multiple sclerosis. Of these, the dementias are responsible for the greatest burden of disease, with Alzheimer’s disease representing over 60-70% of the cases.

Neurodegenerative diseases are strongly linked with age, and the UK and other European countries have an increasingly ageing population. Currently 16% of the European population is over 65, with this figure expected to reach 25% by 2030. In the UK it has been estimated that dementia alone costs the economy £17 billion a year.

The MRC joined forces with the National Institute for Health Research (NIHR) to look at how we could best illustrate the dementias research landscape in the UK. Click through to take a look at our picture

MRC Dementias initiatives

In November 2015 the MRC announced the UK Dementia Research Institute which will lead the UK dementias research efforts and is aimed at transforming treatment and care as well as leading the way in risk reduction strategies for future generations. A further £100M jointly from Alzheimer's Society and Alzheimer's Research UK announced in May 2016 brings the total investment in the Institute up to £250M. The UK Dementia Research Institute will bring together world-leading expertise in biomedical, care, public health and translational dementia research.

In 2014, the MRC launched  the landmark Dementias Platform UK under our ‘Stratified Medicine for Patient Benefit’ initiative on age-related neurodegenerative disease and the dementias. The £53M industry-partnered platform is based around the UK’s strength in cohort studies. The platform is furthering  our understanding of neurodegenerative disease progression and will build the basis for future intervention studies. 

Transnational initiatives

Our activity in neurodegenerative disease research extends beyond the UK, with the MRC leading the development of two international collaborations. The Joint Programming in Neurodegenerative Disease (JPND) and the Centres of Excellence Network (CoEN) initiatives are pooling resources from the UK and other countries across Europe and North America to build collaborative, cross-border research activity in neurodegeneration. 

The EU Joint Programme in Neurodegenerative Disease Research (JPND)

We are a leading partner in a European strategy aimed at coordinating national efforts in neurodegenerative research across the biomedical and social spectrum. The initiative is being conducted through a ‘joint programming’ approach between 30 participating member states. Launched in April 2010, JPND aims to increase coordinated investment between participating countries in research aimed at finding causes, developing cures, and identifying appropriate ways to care for people who have neurodegenerative disease.

Developed under MRC leadership, JPND has created a strategic research agenda (SRA) for neurodegenerative diseases encompassing basic, clinical and socio-economic research. The JPND Research Strategy, which forms the basis of the SRA, was published in early 2012. The JPND partners are now implementing this agenda by proposing innovative ways of pooling expertise and resources to address the fragmentation and duplication of current research efforts across Europe. Implementation includes both calls for proposals and other forms of transnational collaborative activity.

Since 2011 MRC has provided £6m to fund UK participation in 16 transnational JPND projects, with national funding enhanced by European Commission contributions:

In 2014 and 2016, additional JPND awards were made to support expert Working Groups in areas where methodological and structural alignment could be guided through the publication of guidelines and position papers. For each call MRC funded one of the ten €50k (£40k) JPND awards:

Centres of Excellence Network in Neurodegeneration (CoEN)

MRC is a founding partner of CoEN, an international initiative launched in 2010 involving national research funders in the UK, Canada, Germany, France, Flanders, Italy, Republic of Ireland, Slovak Republic and Spain. The initiative links established Centres of Excellence to undertake collaborative neurodegeneration research.

The overall aim of the initiative is to build collaborative, cross-border research activity in neurodegeneration, focusing on adding value to the expertise and critical mass already established within national Centres of Excellence. A long-term goal of CoEN is to provide a mechanism for industry to link to these Centres of Excellence to develop novel and effective industry-academic partnerships in pre-competitive research. CoEN is aligned with the broader JPND, although it operates as an independent entity.

The CoEN ‘Pathfinder’ scheme is distinct from other neurodegeneration transnational funding calls such as JPND and Innovative Medicines Initiative, and for many countries distinct from national grant schemes. Pathfinder calls set out to encourage the community to think ‘outside the box’, to stimulate new and unconventional approaches and creative solutions to the challenges of neurodegeneration research by undertaking high-risk/ high-payoff projects.

The 2017 CoEN Pathfinder call for proposals has been launched by seven of the nine CoEN partners. Further information can be found on the CoEN website.

Since 2011 MRC has provided £2.5m to fund UK participation in 14 of the 24 transnational CoEN projects. 

Details of the 2015 CoEN awards can be found on our news pages: New funding for international cooperation between Centres of Excellence in neurodegenerative disease research

Further details of the initiative can be found on the CoEN website: www.coen.org/home.html

Stigma

In 2014 the International Longevity Centre UK published a report on social stigma around dementia championed by MRC together with Alzheimer's Research UK and the Alzheimer's Society and supported by Pfizer. This report looks at stigma from different perspectives and shines a light on the impact that the fear around dementia has on those living with the condition, their families and carers.  Stigma around dementia prevents the research community from capturing a full picture of the disease and is in itself a little-researched area. The report provides a unique and joined-up focus on the topic.

More information can be found here.

Neurovascular Ageing

Vascular ageing and neurodegenerative diseases are two of the leading health challenges faced by our society, yet there are significant knowledge gaps in current understanding of the biology of ageing as it relates to the central nervous system (CNS), particularly about the interplay between the vasculature and neuronal systems at the mechanistic level.

MRC has brought together the NMHB and PSMB to launch a highlight notice in this area. Proposals may be submitted to the either Board, based on scientific or clinical area.